170 related articles for article (PubMed ID: 24926848)
1. Adaptive sequential testing for multiple comparisons.
Gao P; Liu L; Mehta C
J Biopharm Stat; 2014; 24(5):1035-58. PubMed ID: 24926848
[TBL] [Abstract][Full Text] [Related]
2. Seamless Phase II/III combination study through response adaptive randomization.
Wang L; Cui L
J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
[TBL] [Abstract][Full Text] [Related]
3. Bayesian adaptive D-optimal design with delayed responses.
Li J; Fu H
J Biopharm Stat; 2013 May; 23(3):559-68. PubMed ID: 23611195
[TBL] [Abstract][Full Text] [Related]
4. Group-sequential methods for adaptive seamless phase II/III clinical trials.
Stallard N
J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
[TBL] [Abstract][Full Text] [Related]
5. The Add-Arm Design for Unimodal Response Curve with Unknown Mode.
Chang M; Wang J
J Biopharm Stat; 2015; 25(5):1039-64. PubMed ID: 25331003
[TBL] [Abstract][Full Text] [Related]
6. Adaptive increase in sample size when interim results are promising: a practical guide with examples.
Mehta CR; Pocock SJ
Stat Med; 2011 Dec; 30(28):3267-84. PubMed ID: 22105690
[TBL] [Abstract][Full Text] [Related]
7. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation.
Tamhane AC; Wu Y; Mehta CR
Stat Med; 2012 Aug; 31(19):2041-54. PubMed ID: 22733687
[TBL] [Abstract][Full Text] [Related]
8. Design of randomized controlled trials.
Stanley K
Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
[No Abstract] [Full Text] [Related]
9. Optimal response-adaptive randomized designs for multi-armed survival trials.
Sverdlov O; Tymofyeyev Y; Wong WK
Stat Med; 2011 Oct; 30(24):2890-910. PubMed ID: 21823146
[TBL] [Abstract][Full Text] [Related]
10. Group sequential enrichment design incorporating subgroup selection.
Magnusson BP; Turnbull BW
Stat Med; 2013 Jul; 32(16):2695-714. PubMed ID: 23315698
[TBL] [Abstract][Full Text] [Related]
11. Adaptive Dunnett tests for treatment selection.
Koenig F; Brannath W; Bretz F; Posch M
Stat Med; 2008 May; 27(10):1612-25. PubMed ID: 17876763
[TBL] [Abstract][Full Text] [Related]
12. A case study of modeling and exposure-response prediction for count data.
Quan H; Mao X; Wei L; Wang L
J Biopharm Stat; 2014; 24(5):1073-90. PubMed ID: 24914574
[TBL] [Abstract][Full Text] [Related]
13. Many-to-one comparisons after safety selection in multi-arm clinical trials.
Hlavin G; Hampson LV; Koenig F
PLoS One; 2017; 12(6):e0180131. PubMed ID: 28651023
[TBL] [Abstract][Full Text] [Related]
14. Group Sequential Design for Randomized Phase III Trials under the Weibull Model.
Wu J; Xiong X
J Biopharm Stat; 2015; 25(6):1190-205. PubMed ID: 25322440
[TBL] [Abstract][Full Text] [Related]
15. A class of Covariate-Adjusted Response-Adaptive Allocation Designs for Multitreatment Binary Response Trials.
Biswas A; Bhattacharya R
J Biopharm Stat; 2018; 28(5):809-823. PubMed ID: 29913107
[TBL] [Abstract][Full Text] [Related]
16. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
Xie F; Ji Y; Tremmel L
Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
[TBL] [Abstract][Full Text] [Related]
17. A varying-stage adaptive phase II/III clinical trial design.
Dong G
Stat Med; 2014 Apr; 33(8):1272-87. PubMed ID: 24273128
[TBL] [Abstract][Full Text] [Related]
18. Flexible two-stage design with sample size reassessment for survival trials.
Desseaux K; Porcher R
Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
[TBL] [Abstract][Full Text] [Related]
19. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim.
Posch M; Maurer W; Bretz F
Pharm Stat; 2011; 10(2):96-104. PubMed ID: 22328314
[TBL] [Abstract][Full Text] [Related]
20. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
Chen YH; Li C; Lan KK
Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]